Ongoing Liquidity Challenges

Eevia has faced liquidity constraints for several years. Despite significant reductions in operating costs over the past six quarters and some recovery in revenue following a major customer loss in July 2023 (which accounted for approximately 70% of revenues), the Company operates with genitive EBITDA and remains financially challenged.

Eevia has completed two partially successful rights issues-one in 2024 and another in 2025, gaining close to MEUR 2 in new equity. However, Eevia has not succeeded in securing non-dilutive financing from key Finnish funding institutions, including Finnvera, Business Finland, and the Centre for Economic Development, Transport and the Environment. Notably, nearly all funding applications submitted to these institutions over the past seven years have been declined, including four rejections in the past six months-most recently today, June 12, 2025 from Business Finland.The rejections includes for applications for EU-backed loan and grant instruments such as the InvestEU Sustainability Loan and EU Rural Development Investment Grants, for which Eevia is eligible and has two Seals of Excellence from the European Innovation Council (ie. top score) supporting eligibility.

Strategy and Setbacks

Over the past year, management has worked intensively on a turn-around plan built on committed equity investments and new sales contracts. Eevia has signed several significant new sales contracts recently and implemented initiatives to optimize costs and monetize side-stream products. These investments were contingent on the Company securing matching non-dilutive funding-support that has not materialized. The lack of public financial backing has led key investors to withdraw their commitments, disabling some of the initiatives.

While similar companies (age, size, products, etc.) in other EU countries as well as Finland have secured substantial EU-backed funding through national agencies, Eevia has not received comparable support. As a result, Eevia is now "outfunded" for investments, R&D and process improvement activities and to mitigate the funding gap, it plans to shift its R&D and production activities to more supportive regions for nutrition and health innovation to regain competitiveness.

Immediate Actions

As of June 12, 2025, the Board concludes that unless the Management can rapidly sell out inventory items and realize cash from the inventory, the Company's existing operating capital is insufficient to meet all debt obligations over the next three (3) months. In response, Eevia is launching an urgent fall-back plan that includes:

• Prioritization of sales from inventory to produce cash
• Significant cost reductions and a revised operating model, which will allow sales of certain fixed assets
• Sales focus on high-margin products and "low-hanging" fruits, i.e. high probability opportunities
• A temporary moratorium on all debt payments over the summer, except for critical obligations (e.g., statutory pensions, taxes, utilities, insurance, payroll, etc.). This is to protect non-statutory creditors from uneven payment distribution
• Seeking a bridge loan and then undertake a private placement of new equity based on a new operating model.
• Other actions that will support the situation, including debt-to-equity swaps with approximately 35% of unsecured creditors.

Looking Ahead

Eevia continues to see major commercial opportunities, as demonstrated by recent significant sales contracts with globally recognized partners and industry juggernauts. However, capital is needed to realize these prospects. The Board and Management remain committed to protecting the interests of all shareholders and creditors. To provide clarity for creditors, the Company confirms that it will not pursue public restructuring but rather aims to reorganize and restructure the company operations as well as its obligations privately and voluntarily through out-of-court creditor agreements. This is a challenging and difficult process that will require almost unanimous creditor acceptance, including company's banks. However, the Board and Management consider this approach to be in the best interest of all constituents of our venture.

Audit Status

Uncertainty surrounding the Company's financial position has impacted the audit process, which is delayed and have caused delay in reporting of statutory financial statements, ref. Eevia's financial calendar. An updated timeline (calendar) will be provided soon.

Furthermore, due to uncertainties, Eevia's auditors are challenging the principle of going concern and therefore also certain asset valuations. While the Board and the Management, with the support of external accounting and audit experts, does not consider a liquidation balance sheet (Swedish: "kontrollbalansräkning") to be required, the discussions around valuations have begun to resemble liquidation principles. Hence, to avoid a qualified audit opinion, Eevia's management has agreed to conservative write-downs of certain assets. These write-downs are accounting- and audit-driven and do not necessarily reflect a decline in actual realizable value. They may impact reported equity as of December 31, 2024, but are not expected to impair future operational potential.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com  or investor@eeviahealth.com                     

Telephone: +358 400 22 5967                         

This disclosure contains information that EEVIA HEALTH PLC must make public according to the EU Market Abuse Regulation (EU nr 596/2014). The information was initially submitted for publication through the contact person's agency on June 12, 2025, at 14:50 EEST.

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc is a health ingredient company specialized in sustainable bioactive extracts from wild-harvested Nordic plants and berries. With a focus on gut health, including kidney and urinary health, as well as cellular protection, and inflammation, Eevia offers clinically relevant ingredients to global nutraceutical brands.

Eevia Health, founded in 2017, is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.